Periportal hepatic involvement of non-Hodgkin lymphoma: a rare case report with magnetic resonance imaging findings.

J Int Med Res

Department of Radiology, Recep Tayyip Erdoğan University, School of Medicine, Rize, Turkey.

Published: February 2019

AI Article Synopsis

  • Lymphoma can affect the liver in three main ways: diffuse infiltrative, nodular, and mixed infiltrative-nodular patterns, with periportal involvement being rare.
  • There are limited documented cases of periportal hepatic lymphoma that have included imaging results from ultrasound and CT scans.
  • This case report details a patient with periportal hepatic lymphoma who experienced obstructive jaundice, highlighting findings from CT, MRI, and diffusion-weighted MRI, along with histopathological results.

Article Abstract

Lymphoma with hepatic involvement can present with three morphological patterns: diffuse infiltrative, nodular, and mixed infiltrative-nodular. However, lymphoma with periportal infiltrative hepatic involvement is rare. There have been a few reports of cases with this type of hepatic involvement including ultrasound or computed tomography (CT) findings. In this case report, we present CT, magnetic resonance imaging (MRI), and diffusion-weighted MRI findings together with the histopathological results for a patient with periportal hepatic lymphoma presenting with obstructive jaundice.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381464PMC
http://dx.doi.org/10.1177/0300060518810869DOI Listing

Publication Analysis

Top Keywords

hepatic involvement
16
periportal hepatic
8
case report
8
report magnetic
8
magnetic resonance
8
resonance imaging
8
involvement
4
involvement non-hodgkin
4
lymphoma
4
non-hodgkin lymphoma
4

Similar Publications

The role of ferroptosis in liver injury after cold ischemia-reperfusion in rats with autologous orthotopic liver transplantation.

J Artif Organs

January 2025

Department of Anesthesiology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430070, China.

Using autologous orthotopic liver transplantation (AOLT) model in rats, the effect of lipid reactive oxygen species (L-ROS) inhibitor Ferrostain-1 on ferroptosis signal pathway was observed to determine whether ferroptosis occurred in rat liver injury after cold ischemia-reperfusion (I/R). Thirty-two healthy adult SPF male SD rats, 8 ~ 10 weeks old, weight 240 ~ 260 g, were divided into four groups by the method of random number table (n = 8): sham group, I/R group, I/R + Fer-1 group, I/R + DFO group. In the I/R + Fer-1 group, ferristatin-1(5 mg /kg) was intraperitoneally injected 30 min before surgery; in the I/R + DFO group, DFO 100 mg/kg was injected intraperitoneally 1 h before operation and 12 h after operation.

View Article and Find Full Text PDF

Gliclazide is a sulfonylurea hypoglycemic agent used to treat type 2 diabetes. Cytochrome P450 (CYP) 2C9 and CYP2C19 are primarily involved in the hepatic metabolism of gliclazide. The two CYP isozymes are highly polymorphic, and their genetic polymorphisms are known to significantly impact the pharmacokinetics of gliclazide.

View Article and Find Full Text PDF

Hepatic insulin clearance is essential for maintaining glucose homeostasis and is closely linked to metabolic disorders such as obesity, insulin resistance, and diabetes. Accurate measurement of insulin clearance is vital for understanding the underlying mechanisms of these conditions. This protocol presents a straightforward and user-friendly hepatic perfusion procedure in mice, specifically designed to directly evaluate the hepatic insulin clearance rate.

View Article and Find Full Text PDF

A 77-year-old male presented for an incidental 5-cm gastroduodenal artery aneurysm (GDAA). He underwent an endovascular GDAA coil embolization with 6 months of no aneurysmal growth on surveillance imaging. His 12-month scan revealed aneurysmal growth from 5 cm to 7.

View Article and Find Full Text PDF

Type 2 diabetes mellitus (T2DM), a metabolic disorder, has the hallmarks of persistent hyperglycemia, insulin resistance, and dyslipidemia. Protein-tyrosine phosphatase 1B (PTP1B) was found to be overexpressed in many tissues in the case of T2DM and involved in the negative regulation of insulin signaling. So, PTP1B inhibition can act as a therapeutic target for T2DM.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!